Peptide Overviews · August 20, 2026

What Is GHK-Cu? The Copper Peptide, and What the Human Trials Actually Found

GHK-Cu infographic: copper-bound tripeptide, 179 indexed papers, and two null topical human trials.

Short answer: GHK-Cu is a real, naturally occurring molecule — the tripeptide glycyl-L-histidyl-L-lysine bound to copper — and it is genuinely better studied than most compounds in this category, with 179 indexed papers and, unusually, randomised controlled trials in humans.

That last point is where it gets interesting, and where most pages about GHK-Cu stop. Both human randomised trials applied it topically to skin, and neither showed an objective benefit over its comparator. The details are below, because they are more useful than another list of claimed benefits.

What GHK-Cu actually is

Structure Glycyl-L-histidyl-L-lysine, a three-amino-acid sequence, complexed with copper(II)
Also called Copper tripeptide-1, copper peptide, GHK, tripeptide-copper complex
Endogenous? Yes — GHK occurs naturally in human plasma, which separates it from most synthetic research peptides
Why it is blue The copper. Reconstituted GHK-Cu solutions are distinctly blue, and it is why GLOW and KLOW blends are blue too
Indexed papers 179 (288 for the broader term “copper tripeptide”)

Counts retrieved from the PubMed E-utilities API on 20 August 2026, using the same search convention as the rest of this library.

The two human randomised trials

Three records are indexed as randomised controlled trials. One is in rabbits. The two human trials are both worth reading in full, and both are topical.

Venous stasis ulcers, 1992 — 86 patients

A prospective, randomised, evaluator-blinded trial compared a 0.4% copper tripeptide cream against silver sulfadiazine and against an inert vehicle placebo, in chronic venous ulcers.

Silver sulfadiazine significantly reduced ulcer size. The copper tripeptide cream did not: in the authors’ words, there was no difference between the copper tripeptide and the placebo. This is the largest randomised human trial of the compound, and its result for GHK-Cu was null.

CO2 laser-resurfaced facial skin, 2006 — 13 patients

Patients undergoing facial laser resurfacing were randomised to post-treatment skincare with or without GHK-Cu. Blinded evaluators and computer analysis found no significant difference in resolution of redness, and objective assessment found no significant improvement in wrinkles or overall skin quality.

One measure did differ: patient-reported satisfaction with overall skin quality was significantly higher in the GHK-Cu group. That is a real finding, but it is a subjective endpoint in thirteen people, and it is not the same as a measured improvement in the skin.

What the preclinical literature examines

None of the above means GHK-Cu is inert. The mechanistic and animal literature is substantial and is where the interest comes from:

  • Extracellular matrix and collagen signalling — effects on fibroblast function, collagen and glycosaminoglycan synthesis.
  • Wound models — 54 of the 179 records involve wound healing contexts, the largest single theme.
  • Copper transport — GHK binds copper(II) with high affinity, and much of the proposed mechanism runs through copper delivery rather than the peptide alone.
  • Gene expression — a widely cited 2018 analysis reports GHK modulating a large number of human genes, which is the basis for most of the broader claims made about it.
  • Skin permeation — an active formulation question, with recent work on liposomal encapsulation specifically because getting the intact complex through skin is difficult.

What the literature does not establish

  • No human trial of injected GHK-Cu. Only 19 of the 179 records mention injection at all, and none is a randomised human trial. A research vial is for injection studies — and that is precisely the route with no human randomised evidence behind it.
  • The two human trials that exist are topical and did not show objective benefit. Stated plainly because most pages on this subject cite the mechanistic work and skip the trials.
  • Only 12 records concern topical application specifically, despite topical being the dominant commercial format.
  • Only 7 records involve hair, despite hair growth being one of the most heavily marketed applications.
  • No approved drug status. GHK-Cu is used in cosmetics; it holds no FDA marketing authorisation as a drug.

A note on who wrote the reviews

This is worth knowing when reading about GHK-Cu, and it is verifiable from the papers themselves rather than a matter of opinion. The most-cited enthusiastic reviews — including the 2018 gene-data paper and the anti-aging review — list their authors’ affiliation as a commercial skin-care research and development company. One of those authors is also the researcher who originally characterised GHK.

That does not make the work wrong, and primary researchers writing reviews of their own field is entirely normal. But a reader weighing the evidence should know that much of the most favourable secondary literature originates with a party that commercialises the compound, and should weight the randomised trials accordingly.

Handling and storage

Lyophilised GHK-Cu ships as a dry powder and is stable at room temperature in transit. Standard practice is cold storage of the sealed vial, protection from light, and refrigeration once reconstituted, with reconstituted material treated as short-lived.

The reconstituted solution is blue — that is the copper complex and it is expected. A colourless solution in a vial labelled GHK-Cu is a reason to check the certificate of analysis.

Frequently asked questions

What does GHK-Cu do?

In laboratory and animal models it is studied for effects on fibroblast function, collagen and extracellular matrix signalling, copper transport and wound repair. What it does in a person, at a measured endpoint, is much less established — the two randomised human trials are described above.

Is GHK-Cu injected or applied to skin?

Commercially, overwhelmingly topical — serums and creams. The published human trial evidence is topical too. Research material supplied as a lyophilised vial is intended for laboratory study, and injection in humans has no randomised evidence behind it.

Is it worth the hype?

That depends entirely on which literature you weight. The mechanistic and animal work is real and substantial. The randomised human evidence is two topical trials, neither of which showed an objective benefit. Pages that present GHK-Cu as proven are citing the former and omitting the latter.

What are the downsides of copper peptides?

No safety profile has been established for injected GHK-Cu in humans, so that question cannot be answered from the literature for that route. For topical cosmetic use the compound has a long commercial history, but that is a different question from the one a research buyer is asking. This page makes no safety claim in either direction.

Why is GHK-Cu in GLOW and KLOW?

It is the largest component of both — 50 mg of the 70 mg GLOW vial and of the 80 mg KLOW vial. See What Is GLOW Peptide? and What Is KLOW Peptide?

Is there a GHK-Cu dosing chart?

Not on this site, deliberately. No validated human dosing exists for injected GHK-Cu, so any chart would be an invented number presented as guidance. Reconstitution arithmetic — how much solvent produces what concentration — is a property of the material and is covered separately.

Research use only

These products are not for human consumption. They are sold strictly for research and educational purposes and are not intended to diagnose, treat, cure, or prevent any disease. GHK-Cu is not an approved drug in the United States. Information here is derived from peer-reviewed literature and public databases, for educational reference only; it does not constitute medical advice or product claims. No dosing guidance appears on this page.

References

  • A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg, 1992. PMID 1495150
  • Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006. PMID 16847171
  • Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol, 2006. PMID 17083573
  • GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int, 2015. PMID 26236730
  • Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci, 2018. PMID 29986520
  • The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther, 2020. PMID 35083444
  • Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? Molecules, 2025. PMID 39795193
  • Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts, 2025. PMID 39963574
  • Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol, 2025. PMID 40672369
  • Record counts retrieved from the PubMed E-utilities API (esearch.fcgi), 20 August 2026.

Research-use product reference: GHK-Cu lyophilised vials and GHK-Cu 2 mg Capsules are listed at Peptide Titans for laboratory research use only, with lot-specific certificates of analysis. It is also the largest component of the GLOW and KLOW blends. Products are not for human consumption.

Related

← Back to all articles